Brightline-2: MDM2 Inhibitor BI 907828 in MDM2 amplified, TP53 Wild Type Pancreatic or Biliary Tract Cancer

Condition: Biliary Tract Cancer, Pancreatic Cancer

Sponsor: Boehringer Ingelheim

Full Title
Brightline 2- A Phase II/III, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type solid tumours-biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors

Study Treatment
Oral MDM2 inhibitor BI 907828

Eligibility/Info
For the treatment of patients with a metastatic biliary tract or pancreatic adenocarcinoma that has progressed on/after treatment with all available standard of care treatment options.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.